IRAK4 and systemic lupus erythematosus: IRAK4 has thus emerged as an attractive therapeutic target for diseases associated with dysregulated inflammation, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), spondylarthritis, and psoriatic arthritis.